Conference
PIH11 IMPACT OF THE RISK SCORING MODEL ON THE COST-EFFECTIVENESS OF PALIVIZUMAB FOR RESPIRATORY SYNCYTIALVIRUS PROPHYLAXIS IN PREMATURE INFANTS WITH A GESTATIONAL AGE OF 32-35 WEEKS IN CANADA
Authors
Lanctot K; Paes B; Francis P; Chiu A; Hui C; Oh P
Volume
11
Pagination
pp. a248-a249
Publisher
Elsevier
Publication Date
May 1, 2008
DOI
10.1016/s1098-3015(10)70785-3
Conference proceedings
Value in Health
Issue
3
ISSN
1098-3015